Jane C Davies1, Samuel M Moskowitz1, Cynthia Brown1, Alexander Horsley1, Marcus A Mall1, Edward F McKone1, Barry J Plant1, Dario Prais1, Bonnie W Ramsey1, Jennifer L Taylor-Cousar1, Elizabeth Tullis1, Ahmet Uluer1, Charlotte M McKee1, Sarah Robertson1, Rebecca A Shilling1, Christopher Simard1, Fredrick Van Goor1, David Waltz1, Fengjuan Xuan1, Tim Young1, Steven M Rowe1. 1. From Imperial College London and Royal Brompton and Harefield NHS Foundation Trust, London (J.C.D.), and the Manchester Adult Cystic Fibrosis Centre, Manchester (A.H.) - both in the United Kingdom; Vertex Pharmaceuticals (S.M.M., C.M.M., S.R., R.A.S., C.S., F.V.G., D.W., F.X., T.Y.) and Boston Children's Hospital and Brigham and Women's Hospital (A.U.) - all in Boston; Indiana University School of Medicine, Indianapolis (C.B.); Universitätsmedizin Berlin and Berlin Institute of Health, Berlin, and the German Center for Lung Research, Giessen - all in Germany (M.A.M.); St. Vincent's University Hospital and University College Dublin School of Medicine, Dublin (E.F.M.), and Cork University Hospital and University College Cork, Cork (B.J.P.) - all in Ireland; Schneider Children's Medical Center of Israel, Petah Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv (D.P.) - both in Israel; Seattle Children's Hospital, Seattle (B.W.R.); National Jewish Health, Denver (J.L.T.-C.); St. Michael's Hospital, Toronto (E.T.); and the University of Alabama at Birmingham, Birmingham (S.M.R.).
Abstract
BACKGROUND: The next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector VX-659, in triple combination with tezacaftor and ivacaftor (VX-659-tezacaftor-ivacaftor), was developed to restore the function of Phe508del CFTR protein in patients with cystic fibrosis. METHODS: We evaluated the effects of VX-659-tezacaftor-ivacaftor on the processing, trafficking, and function of Phe508del CFTR protein using human bronchial epithelial cells. A range of oral VX-659-tezacaftor-ivacaftor doses in triple combination were then evaluated in randomized, controlled, double-blind, multicenter trials involving patients with cystic fibrosis who were heterozygous for the Phe508del CFTR mutation and a minimal-function CFTR mutation (Phe508del-MF genotypes) or homozygous for the Phe508del CFTR mutation (Phe508del-Phe508del genotype). The primary end points were safety and the absolute change from baseline in the percentage of predicted forced expiratory volume in 1 second (FEV1). RESULTS:VX-659-tezacaftor-ivacaftor significantly improved the processing and trafficking of Phe508del CFTR protein as well as chloride transport in vitro. In patients, VX-659-tezacaftor-ivacaftor had an acceptable safety and side-effect profile. Most adverse events were mild or moderate. VX-659-tezacaftor-ivacaftor resulted in significant mean increases in the percentage of predicted FEV1 through day 29 (P<0.001) of up to 13.3 points in patients with Phe508del-MF genotypes; in patients with the Phe508del-Phe508del genotype already receiving tezacaftor-ivacaftor, adding VX-659 resulted in a further 9.7-point increase in the percentage of predicted FEV1. The sweat chloride concentrations and scores on the respiratory domain of the Cystic Fibrosis Questionnaire-Revised improved in both patient populations. CONCLUSIONS: Robust in vitro activity of VX-659-tezacaftor-ivacaftor targeting Phe508del CFTR protein translated into improvements for patients with Phe508del-MF or Phe508del-Phe508del genotypes. VX-659 triple-combination regimens have the potential to treat the underlying cause of disease in approximately 90% of patients with cystic fibrosis. (Funded by Vertex Pharmaceuticals; VX16-659-101 and VX16-659-001 ClinicalTrials.gov numbers, NCT03224351 and NCT03029455 .).
RCT Entities:
BACKGROUND: The next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector VX-659, in triple combination with tezacaftor and ivacaftor (VX-659-tezacaftor-ivacaftor), was developed to restore the function of Phe508del CFTR protein in patients with cystic fibrosis. METHODS: We evaluated the effects of VX-659-tezacaftor-ivacaftor on the processing, trafficking, and function of Phe508del CFTR protein using humanbronchial epithelial cells. A range of oral VX-659-tezacaftor-ivacaftor doses in triple combination were then evaluated in randomized, controlled, double-blind, multicenter trials involving patients with cystic fibrosis who were heterozygous for the Phe508del CFTR mutation and a minimal-function CFTR mutation (Phe508del-MF genotypes) or homozygous for the Phe508del CFTR mutation (Phe508del-Phe508del genotype). The primary end points were safety and the absolute change from baseline in the percentage of predicted forced expiratory volume in 1 second (FEV1). RESULTS:VX-659-tezacaftor-ivacaftor significantly improved the processing and trafficking of Phe508del CFTR protein as well as chloride transport in vitro. In patients, VX-659-tezacaftor-ivacaftor had an acceptable safety and side-effect profile. Most adverse events were mild or moderate. VX-659-tezacaftor-ivacaftor resulted in significant mean increases in the percentage of predicted FEV1 through day 29 (P<0.001) of up to 13.3 points in patients with Phe508del-MF genotypes; in patients with the Phe508del-Phe508del genotype already receiving tezacaftor-ivacaftor, adding VX-659 resulted in a further 9.7-point increase in the percentage of predicted FEV1. The sweat chloride concentrations and scores on the respiratory domain of the Cystic Fibrosis Questionnaire-Revised improved in both patient populations. CONCLUSIONS: Robust in vitro activity of VX-659-tezacaftor-ivacaftor targeting Phe508del CFTR protein translated into improvements for patients with Phe508del-MF or Phe508del-Phe508del genotypes. VX-659 triple-combination regimens have the potential to treat the underlying cause of disease in approximately 90% of patients with cystic fibrosis. (Funded by Vertex Pharmaceuticals; VX16-659-101 and VX16-659-001 ClinicalTrials.gov numbers, NCT03224351 and NCT03029455 .).
Authors: W Dalemans; P Barbry; G Champigny; S Jallat; K Dott; D Dreyer; R G Crystal; A Pavirani; J P Lecocq; M Lazdunski Journal: Nature Date: 1991 Dec 19-26 Impact factor: 49.962
Authors: J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou Journal: Science Date: 1989-09-08 Impact factor: 47.728
Authors: Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn Journal: N Engl J Med Date: 2011-11-03 Impact factor: 91.245
Authors: Jennifer L Taylor-Cousar; Anne Munck; Edward F McKone; Cornelis K van der Ent; Alexander Moeller; Christopher Simard; Linda T Wang; Edward P Ingenito; Charlotte McKee; Yimeng Lu; Julie Lekstrom-Himes; J Stuart Elborn Journal: N Engl J Med Date: 2017-11-03 Impact factor: 91.245
Authors: Steven M Rowe; Cori Daines; Felix C Ringshausen; Eitan Kerem; John Wilson; Elizabeth Tullis; Nitin Nair; Christopher Simard; Linda Han; Edward P Ingenito; Charlotte McKee; Julie Lekstrom-Himes; Jane C Davies Journal: N Engl J Med Date: 2017-11-03 Impact factor: 91.245
Authors: Fredrick Van Goor; Sabine Hadida; Peter D J Grootenhuis; Bill Burton; Jeffrey H Stack; Kimberly S Straley; Caroline J Decker; Mark Miller; Jason McCartney; Eric R Olson; Jeffrey J Wine; Ray A Frizzell; Melissa Ashlock; Paul A Negulescu Journal: Proc Natl Acad Sci U S A Date: 2011-10-05 Impact factor: 11.205
Authors: Claire E Wainwright; J Stuart Elborn; Bonnie W Ramsey; Gautham Marigowda; Xiaohong Huang; Marco Cipolli; Carla Colombo; Jane C Davies; Kris De Boeck; Patrick A Flume; Michael W Konstan; Susanna A McColley; Karen McCoy; Edward F McKone; Anne Munck; Felix Ratjen; Steven M Rowe; David Waltz; Michael P Boyle Journal: N Engl J Med Date: 2015-05-17 Impact factor: 91.245
Authors: Philip H Quanjer; Sanja Stanojevic; Tim J Cole; Xaver Baur; Graham L Hall; Bruce H Culver; Paul L Enright; John L Hankinson; Mary S M Ip; Jinping Zheng; Janet Stocks Journal: Eur Respir J Date: 2012-06-27 Impact factor: 16.671
Authors: Clement L Ren; Rebecca L Morgan; Christopher Oermann; Helaine E Resnick; Cynthia Brady; Annette Campbell; Richard DeNagel; Margaret Guill; Jeffrey Hoag; Andrew Lipton; Thomas Newton; Stacy Peters; Donna Beth Willey-Courand; Edward T Naureckas Journal: Ann Am Thorac Soc Date: 2018-03
Authors: Allison F McCague; Karen S Raraigh; Matthew J Pellicore; Emily F Davis-Marcisak; Taylor A Evans; Sangwoo T Han; Zhongzhou Lu; Anya T Joynt; Neeraj Sharma; Carlo Castellani; Joseph M Collaco; Mary Corey; Michelle H Lewis; Chris M Penland; Johanna M Rommens; Anne L Stephenson; Patrick R Sosnay; Garry R Cutting Journal: Am J Respir Crit Care Med Date: 2019-05-01 Impact factor: 21.405
Authors: Kathleen J Ramos; Patrick J Smith; Edward F McKone; Joseph M Pilewski; Amy Lucy; Sarah E Hempstead; Erin Tallarico; Albert Faro; Daniel B Rosenbluth; Alice L Gray; Jordan M Dunitz Journal: J Cyst Fibros Date: 2019-03-27 Impact factor: 5.482
Authors: Peter G Middleton; Marcus A Mall; Pavel Dřevínek; Larry C Lands; Edward F McKone; Deepika Polineni; Bonnie W Ramsey; Jennifer L Taylor-Cousar; Elizabeth Tullis; François Vermeulen; Gautham Marigowda; Charlotte M McKee; Samuel M Moskowitz; Nitin Nair; Jessica Savage; Christopher Simard; Simon Tian; David Waltz; Fengjuan Xuan; Steven M Rowe; Raksha Jain Journal: N Engl J Med Date: 2019-10-31 Impact factor: 91.245
Authors: Marc J C Scanio; Xenia B Searle; Bo Liu; John R Koenig; Robert Altenbach; Gregory A Gfesser; Andrew Bogdan; Stephen Greszler; Gang Zhao; Ashvani Singh; Yihong Fan; Andrew M Swensen; Timothy Vortherms; Arlene Manelli; Corina Balut; Ying Jia; Wenqing Gao; Hong Yong; Michael Schrimpf; Chris Tse; Philip Kym; Xueqing Wang Journal: ACS Med Chem Lett Date: 2019-10-31 Impact factor: 4.345
Authors: Justin T Marinko; Hui Huang; Wesley D Penn; John A Capra; Jonathan P Schlebach; Charles R Sanders Journal: Chem Rev Date: 2019-01-04 Impact factor: 60.622